- Corporate
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions.
News
- Late-breaking abstracts on increased cure rates and synergistic effects of combinations with eribulin and gemcitabine in solid tumor models
- Enhanced survival in a brain tumor model after single agent treatment
more...
- Total revenue increased by 30% to CHF 59.9 million; 2018 total revenue guidance is increased to CHF 120 - 130 million
- Royalties on Cresemba sales more than doubled to CHF 10.8 million
- Clinical oncology pipeline strengthened through in-licensing of phase 2 panFGFR kinase inhibitor (derazantinib)
- Significant progress made in clinical programs
- Cash position of CHF 247.3 million
more...
Basel, Switzerland, August 13, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its partner Hikma Pharmaceuticals LLC, gained regulatory approval for the antifungal Cresemba® (isavuconazole) in Jordan, which is the first approval of the brand in the Middle East and North Africa (MENA) region.
more...
Basel, Switzerland, August 09, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the start of a clinical phase 3 study with its antibiotic ceftobiprole. The registration study evaluates the safety and efficacy of ceftobiprole in the treatment of patients with bacteremia (bloodstream infections) caused by Staphylococcus aureus.
more...
© 2018 Basilea Pharmaceutica Ltd.
